HERHANGİ BİR ÇIKAR ÇATIŞMASI HERHANGİ BİR ÇIKAR ÇATIŞMASI YOKTUR…YOKTUR…

DR.ARZU DİDEM YALÇIN

Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treatment

Mitosis

Apoptosis

ÇOK HÜCRELİ CANLILARDA

HÜCRE SAYISININ KONTROLÜ

Artışı da Azalışı da

İç (mitokondri) ve dış (DR) apopitotik sinyal yolları. İki sistem arasında etkileşim vardır.

Apoptosis’in Başlatılması(Ölüm Reseptörleri)

Memeli Hücresindeki Major Apoptotik Yollar

Hengartner, M.O. 2000. Nature. 407:770.Green, D. and Kroemer, G. 1998. Trends Cell Biol. 8:267.

Mitokondriyal YolÖlüm Resreptörleri Yolu

FasL

Caspase 3

DDD D

Fas/Apo1/CD95

FADD

Procaspase 8

DISC

Caspase 8

BID

oksidanlar seramid diğerleri

Bcl-2D

Cytochrome c

dATP

Procaspase 9

Apaf -1

dATP

Apaf -1

Caspase 9

Procaspase 3

apoptozom

DNA hasarı

Hücresel Hedefler

DİĞER KASPAZLAR ?

KASPAZ-8 / 10

PROKASPAZ-3 KASPAZ-3

PARP KLİVAJI, DNA DEGRADASYONU

HÜCRE ÖLÜMÜ

PROKASPAZ-8 / 10

FADD?, TRADD?

TRAIL-R1/R2

FLIP

FLIP

TRAIL-R ARACILIKLI HÜCRE ÖLÜMÜ YOLAĞI

HÜCRE YÜZEYİ

N %

MaleFemale

281345

44.955.1

Age

<1920-2930-3940-4950-5960+

415816015110251

0.625.225.624.116.38.2

Educational status

illiterate+literatePrimary school Secondary schoolHigh schoolUniversity

58731234269

0.813.95.037.343.0

Duration of disease (year)Total IgE

X ± SEM7.2 ± 0.2

307.6 ± 14.5

Smoker 107 17.1

Yalçın AD, Öncel S, Akcan A, Eravşar K, Polat HH, Terzioğlu E. Prevalance of allergic asthma, rhinitis and conjunctivitis in over 16 year old individuals in Antalya . Turkiye Klinikleri J Med Sci 2010; 30(3):888-94

Yalçın AD, Ozdemir L, Polat HH. Evaluation of the Patients receiving Allergen-specific Immunotheraphy In Antalya. 2011 (BMJ)

Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation

to Omalizumab treatment

Yalcin AD, Bisgin A, Cetinkaya R, Gumuslu S. Clinical efficacy of omalizumab in severe persistent asthma and co-morbid conditions. The American Journal of Case Reports, 2011;

Yalçın AD. Clinical Efficacy And Side Effect Of Omalizumab . Brat Med Journal 2011; (in press)

Yalçın AD, Bisgin A, Kargi A, Kose S, Terzioğlu E, Gorczynski RM. Efficacy of omalizumab and specific subcutane immunotherapy as a treatment modality in allergic asthmas APAllergy and immunology(in press)

Yalçın AD, Gorczynski RM ,et al. Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment. American journal of Rhinology and allergy.American journal of Rhinology and Allergy. (in press)

Omalizumab (trade name Xolair), a recombinant humanized monoclonal antibody to IgE, is recommended as one (new) option for the treatment of severe persistent allergic (IgE mediated) asthma .

Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation

to Omalizumab treatment

Patient no. Age (y) Sex

Duration of asthma symptoms

Duration of severe persistant asthma

Total serum IgE (IU/mL) Eosinophils mm3 Xolair Dose

1 61 M 25 5 424 950 375 mg q. 2 wk

2 38 M 10 2 446 1050 225 mg q. 2 wk

3 47 F 15 4 273 540 225 mg q. 2 wk

4 41 F 10 4 488 560 300 mg q. 2 wk

5 16 F 15 2 542 840 300 mg q. 2 wk

6 56 F 10 2 135 520 300 mg q. 2 wk

7 49 F 5 1 348 340 300 mg q. 2 wk

8 33 F 10 2 249 760 300 mg q. 2 wk

9 16 M 10 2 317 520 225 mg q. 2 wk

10 58 M 6 1 485 970 300 mg q. 2 wk

11 47 F 12 2 650 458 300 mg q. 2 wk

12 35 F 10 2 840 690 300 mg q. 2 wk

13 50 M 6 1 320 450 300 mg q. 2 wk

14 47 M 9 4 920 840 300 mg q. 2 wk

Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation

to Omalizumab treatment

Patient no. Second group (Age and sex) Duration of asthma symptoms ( Second group) Third group (Age and sex)

1 57 M 2 57 M

2 41 M

1 38 M

3 44 F 2 46 F

4 42 F 2 41 F

5 18 F 2 17 F

6 60 F 1 56 F

7 48 F 2 48 F

8 38 F 1 35 F

9 21 M 1 16 M

10 57 M 3 60 M

11 47 F 1 47 F

12 38 F 1 40 F

13 50 M 2 52 M

14 52 M 1 53 M

Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation

to Omalizumab treatment

The results for patients in both groups were compared with those of healthy subjects. These data were analyzed using SPSS version 13.0 for Windows (SPSS Inc., Chicago, IL, USA). Independent two samples t-test were used for comparison of two intergroups. Wilcoxon's matched-pairs signed-rank test were used for comparison of two dependent intergroups.

Serum sTRAIL levels in all individuals (patients and healthy controls) were measured by a sandwich enzyme-linked immunosorbent assay (Diaclone, France).

Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation

to Omalizumab treatment

TEŞEKKÜRLER arzu didem yalcin adidyal@yahoo.com

Prof.Dr.Reginald M GORCZYNSKI, BA, MD, PhD: Transplant Unit, Division of Cellular & Molecular Biology, Toronto Hospital, University Health Network, Toronto, ON, Canada.

Assoc .Prof. Dr. Ramazan CETINKAYA, MD: Division of Nephrology, Antalya Education and Training Hospital

Prof. Saadet GUMUSLU, PhD: Department of Biochemistry, Akdeniz University Faculty of Medicine

Assoc. Prof. Dr. Sukran KOSE, MD: Allergology and Clinical Immunology Unit, Izmir Tepecik Education and Training Hospital.

Prof. Dr. Ender TERZIOGLU, MD: Department of Allergology and Clinical Immunology, Akdeniz University Faculty of Medicine.